Boston Scientific Gets FDA Approval for Deep Brain Stimulation Therapy Software

Boston Scientific has received the FDA’s premarket approval for its Stimview XT image-guided programming software for use with the company’s Vercise Genus navigator for deep brain stimulation.

The system, which enables clinicians to visualize lead placement in the brains of patients with Parkinson’s disease or essential tremor, can reduce programming time and help with more informed treatment decisions, the company said.

The software was developed in collaboration with Brainlab, a Munich, Germany-based medical technology company.